The shift to use more expensive Western branded drugs, particularly newer agents such as Bristol-Myers Squibb's (NYSE: BMY) Baraclude, Roche's (VX: ROG) Pegasys and Schering-Plough's (NYSE: SGP) Pegintron, will contribute significantly to the expansion of the hepatitis B market in China
















